Biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer

17Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycle is associated with some practical disadvantages. We adopted a biweekly regimen with the same dose density. Patients and Methods: Patients with Eastern Cooperative Oncology Group performance status 0-2 diagnosed with advanced histologically or cytologically confirmed pancreatic cancer and no prior treatment were included in the study. Study combination included 1.5 g/m2 gemcitabine and 175 mg/m2 nab-paclitaxel given every 2 weeks. Survival analysis was performed using the Kaplan–Meier method. Results: Forty-six patients were treated with this regimen. Adverse events were similar to those of the original regimen. Median progression-free and overall survival were 5 and 10 months, respectively. Conclusion: Biweekly gemcitabine/nab-paclitaxel seems to have a similar safety and efficacy profile as the original regimen.

Cite

CITATION STYLE

APA

Kokkali, S., Tripodaki, E. S., Drizou, M., Stefanou, D., Magou, E., Zylis, D., … Ardavanis, A. (2018). Biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer. In Vivo, 32(3), 653–657. https://doi.org/10.21873/invivo.11289

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free